Kang PM, Landau AJ, Eberhardt RT, Frishman WHAngiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J1994 ;127(5):1388-401.1 .
Stamler J., Stamler R., Neaton JDBlood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med1993;153(5):598-615.
4.
Hall WDRisk reduction associated with lowering systolic blood pressure: review of clinical trial data. Am Heart J1999;138(3 Pt 2):225-30.
5.
Dzau VJTissue renin-angiotensin system in myocardial hypertrophy and failure . Arch Intern Med1993;153(8):937-42.
6.
Raizada LD,Yang H., Richards EM, Gelband CH, Sumners C.Brain angiotensin receptor subtypes and their coupling to distinct signal transduction pathways. In: LeRoith D, editor. Advances in Molecular Cellular Endocriology. Stanford, CT: JAI Press; 1999:74-101.
7.
Yamazaki T., Yazaki Y.Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress. J Hum Hypertens1999;13 Suppl 1:S43-7.
8.
van Zwieten PADevelopment and trends in the drug treatment of essential hypertension. J Hypertens Suppl1992;10(7):S1-12.
9.
OByrne S. , Caulfield M.Genetics of hypertension. Therapeutic implications . Drugs1998;56(2):203-14.
10.
Jeunemaitre X., Soubrier F., Kotelevtsev YV et al. Molecular basis of human hypertension: role of angiotensinogen. Cell1992;71(1):169-80.
11.
Davis GK, Roberts DHMolecular genetics of the renin-angiotensin system: implications for angiotensin II receptor blockade. Pharmacol Ther1997;75(1):43-50.
12.
Birkenhager WH, de Leeuw PWNon-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens1999;17(7):873-81.
13.
Villard E., Soubrier F.Molecular biology and genetics of the angiotensin-I-converting enzyme: potential implications in cardiovascular diseases. Cardiovasc Res1996;32(6):999-1007.
14.
Berglund L.A recurrent theme with a new spin:ACE polymorphism and cardiovascular disease [editorial; comment]. J Lab Clin Med1998;131(6):485-6.
15.
Bonnardeaux A., Davies E., Jeunemaitre X. et al.Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension1994;24(1):63-9.
16.
Poirier O., Georges JL, Ricard S. et al. New polymorphisms of the angiotensin II type 1 receptor gene and their associations with myocardial infarction and blood pressure: the ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde. J Hypertens1998;16(10):1443-7.
17.
Kurtz TW, Simonet L., Kabra PM,Wolfe S., Chan L., Hjelle BLCosegregation of the renin allele of the spontaneously hypertensive rat with an increase in blood pressure. J Clin Invest1990;85(4):1328-32.
18.
Jacob HJ, Lindpaintner K., Lincoln SE et al. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell1991;67(1):213-24.
19.
Hilbert P., Lindpaintner K., Beckmann JS et al. Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats. Nature1991;353(6344):521-9.
20.
Deng AY, Dene H., Rapp JPMapping of a quantitative trait locus for blood pressure on rat chromosome 2. J Clin Invest1994;94(1):431-6.
21.
Merrill DC, Granwehr BP, Davis DR, Sigmund CDUse of transgenic and gene-targeted mice to model the genetic basis of hypertensive disorders. Proc Assoc Am Physicians1997; 109(6):533-46.
22.
Stec DE, Sigmund CDModifiable gene expression in mice: kidney-specific deletion of a target gene via the cre-loxP system. Exp Nephrol1998;6(6):568-75.
23.
Kainulainen K., Perola M., Terwilliger J. et al. Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension . Hypertension1999;33(3):844-9.
24.
Kotelevtsev V., Clauser E., Corvol P., Soubrier F.Dinucleotide repeat polymorphism in the human angiotensinogen gene. Nucleic Acids Res1991 ;19(24):6978.
25.
St. Lezin E. , Zhang L.,Yang Y. et al. Effect of chromosome 19 transfer on blood pressure in the spontaneously hypertensive rat. Hypertension1999;33(1 Pt 2):256-60.
26.
Gyurko R., Wielbo D., Phillips MIAntisense inhibition of AT1-receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept1993;49(2):167-74.
27.
Wielbo D., Sernia C., Gyurko R., Phillips MIAntisense inhibition of hypertension in the spontaneously hypertensive rat . Hypertension1995;25(3):314-9.
28.
Tomita N., Morishita R., Higaki J. et al.Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension1995;26(1):131-6.
29.
Phillips MI , Mohuczy-Dominiak D., Coffey M. et al. Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense.Hypertension1997;29(1 Pt 2):374-80.
30.
Zhang YC, Bui JD, Shen L., Phillips MIAntisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation2000;101(6): 682-8.
31.
Zhang JJ, Chao L., Chao J.Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke1999;30(9): 1925-31.
32.
Chao J., Jin L., Lin KF, Chao L.Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens Res1997;20(4):269-77.
33.
Lin KF, Chao J., Chao L.Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther1998;9(10): 1429-38.
34.
Lin KF, Chao J., Chao L.Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension1995;26(6 Pt 1):847-53.
35.
Lin KF, Chao L., Chao J.Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension1997;30(3 Pt 1):307-13.
36.
Iyer SN, Lu D., Katovich MJ, Raizada MKChronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense. Proc Natl Acad Sci USA1996;93(18):9960-5.
37.
Lu D., Raizada MK, Iyer S., Reaves P., Yang H., Katovich MJLosartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension1997;30(3 Pt 1):363-70.
38.
Martens JR, Reaves PY, Lu D. et al. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc Natl Acad Sci USA1998;95(5):2664-9.
39.
Gelband CH, Sumners C., Lu D., Raizada MKAngiotensin receptors and norepinephrine neuromodulation: implications of functional coupling. Regul Pept1998;73(3):141-7.
40.
Katovich MJ , Gelband CH, Reaves P., Wang HW, Raizada MKReversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR . Am JPhysiol1999;277(3 Pt 2):H1260-H1264.
41.
Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med2000;342(3):145-53.
42.
Wang H., Katovich MJ, Gelband CH, Reaves PY, Phillips MI, Raizada MKSustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA. Circ Res1999;85(7):614-22.
43.
Gelband CH, Wang H., Gardon ML et al.Angiotensin I-converting enzyme antisense prevents altered renal vascular reactivity, but not high blood pressure, in spontaneously hypertensive rats. Hypertension2000;35(1 Pt 2):209-13.
44.
Wang H., Reaves PY, Gardon ML et al. Angiotensin I-converting enzyme antisense gene therapy causes permanent antihypertensive effects in the SHR. Hypertension2000;35(1 Pt 2):202-8.
45.
Heckmann U., Ottens E., Zidek W., Vetter H.A circulating hypertensive factor in primary hypertension: effect of antihypertensive therapy. Nephron1987;47(Suppl 1):138-41.
46.
Zidek W., Ottens E., Heckmann U.Transmission of hypertension in rats by cross circulation. Hypertension1989;14(1):61-5.
Association AH.1999Heart and Stroke Statistical Update. Dallas,TX: American HeartAssociation;1999.
49.
Simons M., Edelman ER, DeKeyser JL, Langer R., Rosenberg RDAntisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature1992; 359(6390):67-70.
50.
Abe J., Zhou W., Taguchi J. et al. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun1994;198(1):16-24.
51.
Simons M., Edelman ER, Rosenberg RDAntisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest1994;93(6):2351-6.
52.
Morishita R. , Gibbons GH, Ellison KE et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides . J Clin Invest1994;93(4):1458-64.
53.
Morishita R. , Gibbons GH, Kaneda Y., Ogihara T., Dzau VJPharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene1994;149(1):13-9.
54.
Paquet JL, Baudouin-Legros M., Brunelle G., Meyer P. Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens1990;8(6): 565-72.
55.
Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res1991;68(2):450-6.
56.
Osterrieder W., Muller RK, Powell JS, Clozel JP, Hefti F., Baumgartner HRRole of angiotensin II in injury-induced neointima formation in rats. Hypertension1991;18(4 Suppl):1160-4.
57.
Morishita R. , Gibbons GH, Ellison KE et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest1994;94(3):978-84.
58.
Morishita R. , Gibbons GH, Tomita N. et al. Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: evidence for tissue angiotensin-converting enzyme function . Arterioscler Thromb Vasc Biol2000;20(4):915-22.
